Shanghai Everest Medicines announced a $500 million two-part deal with Providence Therapeutics of Calvery, Canada for mRNA products. Initially, Everest will acquire China-Asia rights to Providence 's mRNA clinical stage COVID-19 vaccine for $50 million upfront and $100 million in profit sharing. The two companies will also enter a 50/50 global collaboration for two additional Providence mRNA prophylactic or therapeutic products, also with a $50 million upfront payment and up to $300 million in sales milestones (which will be paid in Everest stock). More details.... Stock Symbol: (HK 1952) Share this with colleagues: // //